Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case: Robert J. Altman, M.D., University of California at San Francisco (UCSF): Based on an investigation conducted by the institution as well as information obtained by ORI during its oversight review, ORI found that Robert J. Altman, M.D., Research Fellow, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF, committed scientific misconduct by fabricating and falsifying data in research supported by two National Institutes of Health grants. Specifically, Dr. Altman fabricated an experiment related to an ovarian cell line injected intraperitoneally into 12 nude mice. The resulting data were reported in (1) a manuscript in page proof entitled \`\`Inhibiting vascular endothelial growth factor arrests growth of ovarian cancer in an intraperitoneal model\'\' (Journal of the National Cancer Institute); (2) a manuscript entitled \`\`Vascular endothelial growth factor is essential for human ovarian carcinoma growth in vivo,\'\' submitted to the Journal of Clinical Investigation (JCI manuscript); and (3) a published abstract entitled \`\`Vascular endothelial growth factor is essential for ovarian cancer growth in vivo\'\' (Society for Gynecologic Investigation, abstract \#079). Further, in the JCI manuscript, Dr. Altman (1) falsified the number of subjects with ovarian tumors from whom he obtained sections of tissue for examination of the expression of vascular endothelial growth factor (VEGF) purportedly by both in situ hybridization and immunohistochemistry, and (2) falsely reported that VEGF expression was examined by in situ hybridization and immunohistochemistry in papillary serous- (n=7) and mucinous- (n=5) cystadenocarcinomas, when the number of surgical cases involving papillary serous tumors was four and the number of mucinous tumors was zero. Dr. Altman examined VEGF expression in only three papillary serous tumor specimens, one specimen both ιin situ and by immunohistochemistry and the remaining two solely by immunohistochemistry. Dr. Altman has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning June 11, 1996, to exclude himself from: (1) Any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations), and (2) Serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. The above voluntary exclusion shall not apply to Dr. Altman\'s future training or practice of clinical medicine whether as a medical student, resident, fellow, or licensed practitioner, as the case may be, unless that practice involves research or research training.
